For the full year (end-December), ViewRay posted preliminary revenues of about $57 million, down from $88 million at the end of fiscal year 2019. ViewRay President and CEO Scott Drake attributed the decline to the COVID-19 pandemic's impact on the business.
For the fourth quarter, ViewRay reported preliminary revenues of $18 million, up from $17 million in the fourth quarter of 2019. The company said it also received five new orders for its MRIdian MRI-guided radiation therapy system in the quarter.
Despite the full-year results, Drake said the company closed the year with a solid final quarter. Drake was particularly encouraged by the commercial activity in the company's pipeline, including the five recent orders.
Copyright © 2021 AuntMinnie.com